Table 1. Characteristics of patients.
| Characteristics | VKA | DOAC | p | |
|---|---|---|---|---|
| Patients, No. (%) | 5699 (79.7) | 1455 (20.3) | ||
| Age | ||||
| median (IQR), y | 78 (69–84) | 75 (67–82) | <0.0001 | |
| ≥75 y, No. (%) | 3516 (61.7) | 763 (52.4) | <0.0001 | |
| Male, No. (%) | 3083 (54.1) | 764 (52.5) | 0.278 | |
| Weight, median (IQR), kg | 76 (66–88) | 78 (66–90) | 0.099 | |
| BMI, median (IQR), kg/m2 | 27.3 (24.3–31.1) | 27.7 (24.5–31.2) | 0.103 | |
| Personnal history, No. (%) | ||||
| Hypertension | 3872 (67.9) | 960 (66.0) | 0.154 | |
| DVT and/or PE | 1514 (26.6) | 239 (16.4) | <0.0001 | |
| Diabetes mellitus | 1307 (22.9) | 315 (21.6) | 0.296 | |
| Coronaropathy and/or MI | 1178 (20.7) | 210 (14.4) | <0.0001 | |
| Symptomatique heart failure | 1154 (20.2) | 188 (12.9) | <0.0001 | |
| Stroke and/or TIA | 931 (16.3) | 219 (15.1) | 0.234 | |
| Peripheral arterial disease | 490 (8.6) | 72 (4.9) | <0.0001 | |
| Hemorrage requiring hospitalization | 477 (8.4) | 68 (4.7) | <0.0001 | |
| Anticoagulant, No. (%) | ||||
| Fluindione | 4161 (73.0) | - | ||
| Warfarine | 1112 (19.5) | - | ||
| Rivaroxaban | - | 823 (56.6) | ||
| Dabigatran | - | 544 (37.4) | ||
| Acenocoumarol | 426 (7.5) | - | ||
| Apixaban | - | 88 (6.0) | ||
| Indication for anticoagulation, No. (%) | ||||
| Valvular atrial fibrillation | 594 (10.4) | 60 (4.1) | <0.0001 | |
| Non-valvular atrial fibrillation | 3274 (57.4) | 1111 (76.4) | <0.0001 | |
| DVT/PE | 1257 (22.1) | 208 (14.3) | <0.0001 | |
| Surgery | 36 (0.6) | 29 (2.0) | <0.0001 | |
| Heart valve prothesis | 524 (9.2) | 5 (0.3) | <0.0001 | |
| Other | 459 (8.1) | 83 (5.7) | 0.003 | |
| Unknown | 13 (0.2) | 1 (0.1) | 0.326 | |
| Duration of anticoagulant treatment >1 year, No. (%) | 4848 (85.1) | 788 (54.2) | <0.0001 | |
| CHA2DS2- Vasc / atrial fibrillation (n = 5039) | ||||
| 0 | 44 (1.1) | 40 (3.4) | <0.0001 | |
| 1 | 187 (4.9) | 74 (6.3) | ||
| ≥2 | 3637 (94.0) | 1057 (90.3) | ||
| HASBLED / atrial fibrillation (n = 5039) | ||||
| ≤3 | 3017 (78.0) | 1040 (88.8) | <0.0001 | |
| >3 | 851 (22.0) | 131 (11.2) | ||
VKA: vitamine-k antagonists, DOA: direct oral anticoagulants, BMI: body mass index, DVT: deep vein thrombosis, PE: pulmonary embolism, MI: myocardial infarction, TIA: transient ischemic attack